Aytu Biopharma (AYTU) Equity Ratio (2011 - 2026)

Aytu Biopharma (AYTU) has 16 years of Equity Ratio data on file, last reported at 0.31 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.31, up 11.98% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.31 (up 11.98% YoY), and the FY2025 annual result was 0.15, down 34.92% from the prior year.
• Equity Ratio climbed to 0.31 in Q1 2026 per AYTU's latest filing, from 0.12 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.36 in Q1 2022 and troughed at 0.12 in Q4 2025.
• A 5-year average of 0.26 and a median of 0.26 in 2024 frame the typical range for Equity Ratio.
• On a YoY basis, Equity Ratio climbed as much as 17.65% in 2025 and fell as far as 56.02% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.32 in 2022, then retreated by 22.73% to 0.25 in 2023, then rose by 5.75% to 0.26 in 2024, then slumped by 56.02% to 0.12 in 2025, then jumped by 170.31% to 0.31 in 2026.
• Business Quant data shows AYTU's Equity Ratio at 0.31 in Q1 2026, 0.12 in Q4 2025, and 0.19 in Q3 2025.